From Research at med.fsu.edu Fri Apr 9 15:23:24 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 9 Apr 2021 19:23:24 +0000 Subject: Weekly Funding Opportunities In-Reply-To: <08B3A713-5C33-4232-8DF4-BB45C3D27E53@fsu.edu> References: <08B3A713-5C33-4232-8DF4-BB45C3D27E53@fsu.edu> Message-ID: Mark Foundation for Cancer: Emerging Leader Award The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. The grant amount is $250,000 per year for three (3) years totaling $750,000. Indirect costs are not to exceed 10% of direct costs and are included in total. Eligibility particularities include: * Applicants must be three to nine years from the start of an independent faculty research appointment as of December 31, 2021 (i.e., the official start date of the appointment must fall within the calendar years 2012-2018). * This award is not intended to be the main source of funding for the applicant?s laboratory. Applicants must therefore demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review stage. Letter of intent due May 3, 2021. Med-RA deadline to receive draft documents: April 20. Lung Cancer Research Foundation: Disparities in Lung Cancer While scientific advances steadily continue to reduce lung cancer incidence and deaths, the disease disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic status populations and people from certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality remain, and inequitable receipt of evidence-based lung cancer care continues to compound these disparities. We encourage applications on a wide variety of disparities-related topics including but not limited to the following: * Gender disparities in lung cancer burden * Causes and risk factors for lung cancer among never smokers * Influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care * Genetic and gene-environment interactions * Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes * Contribution of healthcare access and quality to disparities in outcomes * Disparities related to other factors such as geography, socioeconomic status, and age These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. Due May 7, 2021. Med-RA deadline to receive draft documents: April 26. Gerber Foundation: Pediatric Research Grants The Gerber Foundation is dedicated to enhancing the quality of life of infants and young children, with an emphasis on children under three years of age. The foundation is accepting applications for research projects aimed at identifying solutions to common everyday issues and problems in the field of children?s health and nutrition. Of particular interest to the foundation are projects offering substantial promise of meaningful advances in prevention and treatment of disease and those with broad and general applicability. Research program focus areas identified by the foundation include: * Pediatric Health ? Projects that promote health and prevent or treat disease. Of particular interest to the foundation are applied research projects focused on reducing the incidence of neonatal and early childhood illnesses, or those improving cognitive, social, and emotional aspects of development. * Pediatric Nutrition ? Projects that assure adequate nutrition to infants and young children, including applied research that evaluates the provision of specific nutrients and their related outcomes. * Environmental Hazards (Nutrient Competitors) ? Projects that document the impact of, or ameliorate the effects of, environmental hazards on the growth and development of infants and young children. Major target areas for research include new diagnostic tools that may be more rapid, more specific, more sensitive, or less invasive; treatment regimens that are novel, less stressful or painful, more targeted, have fewer side effects, and/or provide optimal dosing; symptom relief; preventative measures; assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.); and risk assessment tools or measures for environmental hazards, trauma, etc. The foundation is interested in supporting projects that will result in ?new? information, treatments, or tools that result in a change in practice; it rarely funds projects that are focused on sharing current information with parents or caregivers. Grants of up to $350,000 over up to three years will be awarded. Novice researchers follow the same process as regular grants, are limited to no more than $20,000 in total funding, and need to apply under the guidance of a mentor. Concept paper due May 15, 2021 and November 15, 2021. Med-RA deadline to receive draft documents for May 15 due date: May 3. Chan Zuckerberg Initiative: Ancestry Networks for the Human Cell Atlas To cure, prevent, or manage all diseases, scientific research should include people of all ancestries. To help advance that vision, the Chan Zuckerberg Initiative (CZI) has launched a new funding opportunity aimed at expanding the ancestral diversity of the samples in the Human Cell Atlas (HCA), an international effort to map all cells in the human body as a foundational resource for understanding health and disease. Diseases manifest differently in different people, and ancestry is one factor that impacts disease severity, outcome, and treatment. Individuals of European ancestry account for 80 percent of genomics data, and studies based on a narrow slice of ancestral background are often not generalizable to all people. To help fill these gaps in scientific knowledge, the Ancestry Networks for the Human Cell Atlas Request for Applications (RFA) will support teams of researchers to generate healthy, single-cell reference data from historically understudied populations. The Ancestry Networks RFA builds off of CZI?s experience supporting the work of ten collaborative research teams that studied tissue samples from a diversity of populations, including people who are Black, Latinx, Asian, and Indigenous, as an initial step in addressing equal representation in the HCA. The new RFA will support collaborative networks of researchers for three-year projects. Teams should consist of at least three and up to ten principal investigators, including at least one computational biologist or data scientist and one expert in single-cell biology. Community-based participatory researchers should be involved in the collaboration to ensure that the research is attuned to the needs of and connected with the participating donor communities. Ancestry Networks will collectively generate new tools, open source analysis methods, and openly available data from underrepresented donors across multiple tissue types and will provide valuable contributions to the HCA community. Example projects could include the generation of data from organs and tissues from a single or multiple ancestral groups; the development and sharing of tissue resources that will support standards, protocols, and tissue access to researchers; and the expansion of community engagement or donor recruitment programs and models. Due May 25, 2021. Med-RA deadline to receive draft documents: May 12. Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed) The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and inequities. Due May 28, 2021. Med-RA deadline to receive draft documents: May 17. Louisa M. McGregor Ovarian Cancer Foundation (T.E.A.L.): Medical Research and Awareness Program Beneficiary The Tell Every Amazing Lady? About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation 2021 Medical Research Program offers funding in support of ovarian cancer research studies that are most aligned with their mission as determined by the T.E.A.L.? board of directors and scientific advisory board. The mission of T.E.A.L.? is to promote public awareness of and education about the signs, symptoms, and risk factors of ovarian cancer, provide support to survivors, and raise funds for research in order to find a cure. Budget: $15,000 per year; no IDC. Due May 31, 2021. Med-RA deadline to receive draft documents: May 17. Developing Digital Therapeutics for Substance Use Disorders (UG3 / UH3 Clinical Trial optional) The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD.The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. Due August 4, 2021; December 6, 2021; August 4, 2022; December 6, 2022; August 4, 2023; December 6, 2023. Med-RA deadline to receive draft documents for August 4, 2021 due date: July 22. NSF: Cognitive Neuroscience The Cognitive Neuroscience Program seeks highly innovative proposals aimed at advancing a rigorous understanding of the neural mechanisms of human cognition. Central research topics for consideration by the program include attention, learning, memory, decision-making, language, social cognition, and emotions. Proposals with animal models are appropriate only if they include a comparative element with human subjects. Proposals focused on behavioral, clinical or molecular mechanisms will not be considered for this program. Additionally, proposals directed at understanding low-level sensorimotor processes or restricted to model-based simulations of neural data will not be considered, unless they are embedded in a cognitive question related to one of the central research topics listed above. August 13, 2021; February11, 2022; and August 13, 2022. Med-RA deadline to receive draft documents for August 13, 2021 due date: August 2. Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional) This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities. Due August 24, 2021. Med-RA deadline to receive draft documents: August 11. NSF / NIH: Science of Science Policy Approach to Analyzing and Innovating the Biomedical Research Enterprise (SCISIPBIO) SCISIPBIO supports research that advances the scientific basis of science and innovation policy, with a focus on the biomedical sciences. Consistent with the SciSIP program, SCISIPBIO will fund the development of models, analytical tools, data and metrics that can inform science policy and the development of the scientific enterprise. SCISIPBIO welcomes individual and collaborative research projects and places a high priority on interdisciplinary research and on broadening participation. Due September 9, 2021 and February 10, 2022. Med-RA deadline to receive draft documents for September 9 due date: August 26 (due to Labor Day holiday). NIH Director?s Pioneer Award Program (DP1 Clinical Trial Optional) The NIH Director?s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation?s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator?s research program or elsewhere. The NIH Director?s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due September 10, 2021. Med-RA deadline to receive draft documents: August 30. Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer?s Disease and Related Dementias (R25 ? Clinical Trial Not Allowed) The objective of this FOA is to support short-term intensive courses or summer institutes for skills development on one of the three topics below; these have been identified by the National Institute on Aging as high priority needs in order to advance behavioral and social sciences research on AD/ADRD. This FOA particularly encourages development of courses that have a broad reach (i.e., beyond the applicant institution, and/or can be widely disseminated), as the goal of this FOA is to make the educational courses available to a wide range of investigators. Consideration should be given to course design that allows for virtual participation of both students and faculty, and plans for archiving and making publicly available didactic content including course curricula and videotaped lectures. In addition, courses should be designed to help recruit new and diverse research investigators into aging research and to provide participants with both formal and informal opportunities to interact with one another and with course faculty (in order to provide individual attention and to facilitate the formation of research collaborations). Finally, responsive applications will incorporate material on how the particular methodology or topic of focus can be employed to improve scientific understanding of the mechanisms underlying disparities in AD/ADRD or how they can be reduced. Due October 4, 2021. Med-RA deadline to receive draft documents: September 21. Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 ? Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement (FOA) is to support short courses geared towards advancing selected priority topic areas identified by the National Institute on Aging (NIA) in order to advance research in the behavioral and social sciences. This FOA targets the following three priority research areas: 1) genomics for social scientists; 2) interdisciplinary social science research in aging; and 3) reproducibility in the social and behavioral sciences. Responsive applications will incorporate material on how the particular methodology or topic of focus can be employed to improve scientific understanding of the mechanisms underlying disparities in the aging process/aging outcomes or how such disparities can be reduced. Additional goals of the FOA are to help recruit new and diverse research investigators into aging research and to provide course participants with formal and informal opportunities to interact with one another and with course faculty (in order to provide individual attention and to facilitate the formation of research collaborations). Due October 4, 2021. Med-RA deadline to receive draft documents: September 21. Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed); Center for Tobacco Products The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) ? Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey, the National Heart, Lung and Blood Institute?s Biologic Specimen and Data Repository Information Coordinating Center, and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA?s regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA-CTP. October 8, 2021; August 8, 2022; and March 8, 2023. Med-RA deadline to receive draft documents for October 8 due date: September 27. Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) ? Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the US. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA?s regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA-CTP. Due October 8, 2021; August 8, 2022; and March 8, 2023. Med-RA deadline to receive draft documents for October 8 due date: September 27. BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so that they can be integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations. Due October 15, 2021; June 10, 2022; October 14, 2022; June 9, 2023; October 13, 2023; and June 7, 2024. Med-RA deadline to receive draft documents for October 15, 2021 due date: October 4. Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. Due November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024. Med-RA deadline to receive draft documents for November 8, 2021 due date: October 26. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Apr 16 08:27:34 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 16 Apr 2021 12:27:34 +0000 Subject: Weekly funding opportunities In-Reply-To: <267F4738-FA49-4E72-9B11-E30DB4A708E0@fsu.edu> References: <267F4738-FA49-4E72-9B11-E30DB4A708E0@fsu.edu> Message-ID: NCCN/Pfizer/Astellas: Enzalutamide in the Treatment of Prostate Cancer The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and its combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other approaches) within prospective trials or datasets will be accepted. The following are selected priority areas to encourage the development of novel treatment approaches because of their ability to impact the unmet needs for patients with potentially lethal prostate cancer: * Earlier disease states * Treatment and biology of oligometastatic disease * Populations with unique vulnerabilities * Innovative treatment strategies * Specific disease settings in which enzalutamide may offer value * Next generation imaging * Biomarkers of enzalutamide response (including imaging) * Strategies to improve the therapeutic index of enzalutamide Letter of intent due May 14, 2021. Med-RA deadline to receive draft documents: May 3. Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3 / UH3 Clinical Trial Optional) The purpose of this FOA is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy- related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality. Due May 20, 2021. Med-RA deadline to receive draft documents: May 10. NINDS Program Project Grant (P01 Clinical Trial Optional) This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants. Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for May 25, 2021 standard date: May 12. AAV Vector manufacturing for diseases affecting very small populations (R01) Clinical Trials Not Allowed The Center for Biologics Evaluation and Research seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors. Due May 28, 2021. Med-RA deadline to receive draft documents: May 17. NIST Standards Services Curricula Development Cooperative Agreement Program (SSCD CAP) The NIST Standards Services Curricula Development Cooperative Agreement Program (SSCD CAP) is seeking applications from eligible applicants to develop undergraduate and/or graduate level curricula to incorporate documentary standards, standards development, and standardization information and content into seminars, modules, courses, and learning resources. The recipients will work with NIST to strengthen education and learning about documentary standards, standards development, and standardization. Due June 1, 2021. Med-RA deadline to receive draft documents: May 18. Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01) R01: Clinical Trial Optional R01: Clinical Trial Not Allowed The purpose of these Funding Opportunity Announcements (FOAs) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. These FOAs specify a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. These FOAs define ?innovation? as likelihood to deliver a new capability to end users. Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24. Research on Autism Spectrum Disorders (R03 / R21 / R01 Clinical Trial Optional) R03 R21 R01 The purpose of these Funding Opportunity Announcements is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders. Standard dates apply. Expires March 6, 2024. Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24; July 16, 2021 standard date: June 3. Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 / R01 Clinical Trial Required) R34 NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. R01 NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. Standard dates apply. Expires March 17, 2024. Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24; July 16, 2021 standard date: June 3. Congressionally Directed Medical Research Programs Epilepsy Research Program Idea Development Award Pre-application (required letter of intent): June 14. Full application: July 21. Quality of Life Award Pre-application (required letter of intent): June 14. Full application: July 21. Research Partnership Award Pre-application (required letter of intent): June 14. Full application: July 21. Med-RA deadline to receive draft documents for full application: July 8. Ovarian Cancer Research Program Omics Consortium Award Pre-application (required letter of intent): June 24. Full application: July 8. Med-RA deadline to receive draft documents for full application: June 24 (due to July 4 holiday). Peer Reviewed Alzheimer?s Research Program Convergence Science Research Award Pre-application (required letter of intent): June 14. Full application: July 21. Innovation in Care and Support Award Pre-application (required letter of intent): June 14. Full application: July 21. Research Partnership Award Pre-application (required letter of intent): June 14. Full application: July 21. Accelerating Diagnostic Research Award Pre-application (required letter of intent): June 14. Full application: July 21. Leveraging Approaches for Innovation in Care and Support Award Pre-application (required letter of intent): June 14. Full application: July 21. Med-RA deadline to receive draft documents for full application: July 8. Prostate Cancer Research Program Early Investigator Research Award Pre-application (required letter of intent): June 17. Full application: July 1. Confidential letters of recommendation: July 7. Physician Research Award Pre-application (required letter of intent): June 17. Full application: July 1. Confidential letters of recommendation: July 7. Med-RA deadline to receive draft documents for full application: June 21. Translational Science Award Pre-application (required letter of intent): July 15. Full application: July 29. Health Disparity Research Award Pre-application (required letter of intent): July 15. Full application: July 29. Med-RA deadline to receive draft documents for full application: July 16. Idea Development Award Pre-application (required letter of intent): September 2. Full application: September 23. Clinical Consortium Award Pre-application (required letter of intent): September 2. Full application: September 23. Med-RA deadline to receive draft documents for full application: September 13. Data Science Award Pre-application (required letter of intent): July 15. Full application: July 29. Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award Pre-application (required letter of intent): July 15. Full application: July 29. Med-RA deadline to receive draft documents for full application: July 19. Spinal Cord Injury Research Program Clinical Trial Award Pre-application: May 24, 2021. Invited full application: September 3, 2021. Translational Research Award Pre-application: May 24, 2021. Invited full application: September 3, 2021. Investigator Initiated Research Award Pre-application: May 24, 2021. Invited full application: September 3, 2021. Med-RA deadline to receive draft documents for pre-application: May 11. Tuberous Sclerosis Complex Research Program Exporation Hypothesis Development Award Pre-application (required letter of intent): June 17. Full application: July 8. Idea Development Award Pre-application (required letter of intent): June 17. Full application: July 8 Clinical Translational Award Pre-application (required letter of intent): June 17. Full application: July 8. Med-RA deadline to receive draft documents for full application: June 24 (due to July 4 holiday). Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Projects that will be considered for Pfizer support will focus on several or one specified area: * Early identification, evaluation, diagnosis, prognosis and treatment * Study of hereditary ATTR genotypes and phenotypes: * Non-Val30Met genotypes * Val122Ile, Thr60Ala, Val30Met, and others * Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy) * Use of tafamidis in the clinical setting (i.e. real-world evidence) Due June 9, 2021. Med-RA deadline to receive draft documents: May 26 (due to Memorial Day holiday). Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed) The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration and synergies across consortium member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development of reports and analyses summarizing and integrating the findings/products of the consortium. Due June 9, 2021 and November 8, 2021. Med-RA deadline to receive draft documents for June 9, 2021 due date: May 26 (due to Memorial Day holiday). Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 / R01 Clinical Trial not Allowed) R21 R01 These Funding Opportunity Announcements solicit applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI?s other technology development goals. Due June 25, 2021; March 1, 2022; and February 1, 2023. Med-RA deadline to receive draft documents for June 25, 2021 due date: June 14. Intramural ? Extramural Collaboration for Drug Screening with Biofabricated 3-D Disease Tissue Models (UH2 / UH3 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to promote partnerships between intramural investigators at the NCATS 3-D Bioprinting Laboratory and extramural researchers to jointly develop and demonstrate the use of 3-D biofabricated tissues for disease modeling and drug screening. Due June 28, 2021. Med-RA deadline to receive draft documents: June 15. 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center. Due June 30, 2021 and November 22, 2021. Med-RA deadline to receive draft documents for June 30, 2021 due date: June 17. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Apr 21 12:55:33 2021 From: Research at med.fsu.edu (med-Research) Date: Wed, 21 Apr 2021 16:55:33 +0000 Subject: Weekly Funding Opportunities In-Reply-To: <5C48AA44-7DF3-40A2-A5CC-28BC8215DCD2@fsu.edu> References: <5C48AA44-7DF3-40A2-A5CC-28BC8215DCD2@fsu.edu> Message-ID: PhRMA Foundation: Research Starter Grants in Drug Discovery and Drug Delivery Drug Discovery The PhRMA Foundation Research Starter Grant in Drug Discovery offers financial support to individuals beginning independent research careers at the faculty level in drug discovery research. $100,000 for one-year projects. Those holding the academic rank of assistant professor (or research assistant professor) within a tenure track (or research track) appointment, or instructor, if eligible to apply for independent research funding by their institution, are eligible to apply for these research starter grants, providing their proposed research is neither directly nor indirectly already being subsidized to any significant degree by an extramural support mechanism. Individuals receiving only intramural funding or start-up funding from their institution are eligible to apply for Research Starter Grant (RSG) awards. Drug Delivery The PhRMA Foundation Research Starter Grant in Drug Delivery offers financial support to individuals beginning independent research careers at the faculty level in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology or biomedical engineering. $100,000 for one-year projects. Those holding the academic rank of assistant professor (or research assistant professor) within a tenure track (or research track) appointment, or instructor, if eligible to apply for independent research funding by their institution, are eligible to apply for these research starter grants, providing their proposed research is neither directly nor indirectly already being subsidized to any significant degree by an extramural support mechanism. Individuals receiving only intramural funding or start-up funding from their institution are eligible to apply for Research Starter Grant (RSG) awards. Letter of intent due May 20, 2021. Med-RA deadline to receive draft documents: May 10. Alzheimer?s Drug Discovery Foundation: Accelerating Drug Discovery for Frontotemporal Degeneration There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD) and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer?s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). Drug targets in the areas of inflammation and proteostasis will be considered high priority. The RFP supports: * Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME. * In vivo testing of novel lead compounds, biologics, vaccines, or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies. One-year projects; $100,000-$150,000 based on stage and scope of research. Letter of intent due May 28, 2021. Med-RA deadline to receive draft documents: May 17. When Everyone Survives Foundation: Leukemia Research Grants This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of ?When Everyone Survives?. Renewal of initial research support may be considered for one or more additional years based upon productivity. Due June 1, 2021. Med-RA deadline to receive draft documents: May 18. Genentech: Scientific Project Support Scientific Project Support provides funding for general research, translational research, other research or development projects, and/or other initiatives of research organizations, labs, and academic institutions. As part of our company-wide commitment to ensuring a healthier future for all patients, we prioritize projects that build a more fair and just healthcare system in the following areas: * Inclusive research: Reducing barriers to participation in clinical trials so healthcare solutions are designed for all patients * Equity in care: Ensuring all patients have access to high quality care * Future life sciences workforce: Create sustainable pathways into the life sciences for underrepresented groups, particularly low-income students of color Research collaborations, clinical trials, and associated correlative research involving or undertaken in relation to Genentech or Roche products (whether investigational and/or approved for other uses) are excluded from this type of support. Genentech prioritizes action-oriented research projects that are designed to build the evidence base needed to promote health equity and reduce disparities in healthcare access, quality, and outcomes amongst populations facing the greatest needs. Evidence generated from Scientific Projects should support health systems and hospitals, practitioners, advocates, and decision-makers in setting priorities and allocating resources towards solutions that improve the health and wellbeing of all patients within Genentech?s disease areas of focus. Operating expenses must be directly and exclusively dedicated to the activity for which the requestor is applying. Genentech/Roche will consider funding requests in the following disease states: bladder cancer, breast cancer, metastatic breast cancer, HER2-positive metastatic breast cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancy, hemophilia, leukemia, lung cancer, lymphoma, waldenstrom?s macroglobulinemia, melanoma, multiple sclerosis, myeloma, non-hodgkins lymphoma, ovarian cancer, and pan-tumor. Applications accepted any time. Med-RA deadline to receive draft documents: ten business days before submission to sponsor. Foundation for OCD Research: Seed Grants FFOR is seeking applications for innovative, potentially high-impact pre-clinical, translational or clinical research from investigators around the world. We seek to support projects that have the potential to significantly advance the understanding of the pathophysiology of OCD and/or improve the treatment of severe OCD. Examples of relevant research include, but are not limited to studies that aim to: * Discover the molecular, cellular, synaptic, or circuit basis of prominent OCD symptoms in model organisms or humans. * Identify and/or test pharmacological and non-pharmacological therapeutic targets. * Advance biomarker development for OCD to improve diagnoses and/or treatment outcomes. * Explore the role of the immune system or microbiome in OCD. * Develop new models or refine existing models of OCD 3-year projects, $200,000 a year in direct costs, 10% IDC. Letter of intent due June 15, 2021. Med-RA deadline to receive draft documents: June 2. Robert Wood Johnson Foundation: Transforming Health and Health Care Systems The purpose of this Transforming Health and Health Care Systems call for proposals is to fund research studies that evaluate or predict how enrollees are effected by Medicaid policy changes enacted in response to the COVID-19 pandemic. Given the disproportionate impact of the pandemic on communities of color, we are requesting studies that examine the impact of Medicaid policies on communities of color and/or explore how current or proposed policies may alleviate or exacerbate racial inequity and structural racism in the context of Medicaid. The goal of this funding opportunity is to generate rigorous evidence on the effects of recent Medicaid policy changes on enrollees, states, and others, and to inform and advance equitable policies and racial equity in Medicaid. Due June 28, 2021. Med-RA deadline to receive draft documents: June 15. Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Black Children and Adolescents (R34 / R01 Clinical Trial Optional) R34 This initiative supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB), and non-suicidal self-injury (NSSI) specifically among Black children and adolescents. Applications should focus on developmental work that would enhance the probability of success in subsequent larger scale R01 projects. Research generating new information about factors causing/reducing disparities is strongly encouraged, along with due consideration for the variation in developmental needs across children and youth. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This Funding Opportunity Announcement (FOA) invites development of interventions and strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the future implementation of interventions that are proven effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the intervention under development should account for individual-, family-, community-, provider-, and organizational-level factors necessary to optimize effectiveness, feasibility, and rapid uptake, implementation, and sustained delivery, thereby accelerating the benefit to the population. The intervention should also improve connections to preventive and treatment interventions with proven effectiveness in reducing suicide and suicidal ideation and behaviors, with the goal of making these interventions more available, accessible, and more effectively delivered to Black youth, in a sustained and coordinated way. This FOA encourages pilot research focused on the development of systems-level interventions and is not intended to support development or testing of new screening tools, assessment instruments, or pilot studies for the development of individual-level preventive or therapeutic interventions. R01 This initiative supports research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB) and/or non-suicidal self-harm (NSSI) among Black children and adolescents. Specifically, this Funding Opportunity Announcement (FOA) encourages services research on the effectiveness-implementation continuum aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI, among Black children and adolescents. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This FOA invites testing of interventions and strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the systems-level interventions and strategies should also account for individual-, family-, community-, provider-, and organizational-level factors to optimize the effectiveness, feasibility, and rapid uptake, implementation, and sustained delivery, thereby accelerating the benefit to the population. This research should also improve connections to preventive and treatment interventions with proven effectiveness in reducing SIB or NSSI, with the goal of making these interventions more available, accessible, and more effectively delivered to Black youth, in a sustained and coordinated way. This FOA encourages research focused on systems-level interventions and is not intended to support the development or testing of new screening tools, assessment instruments, or individual-level preventive or therapeutic interventions. Due June 29, 2021. Med-RA deadline to receive draft documents: June 16. Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R34 / R01 Clinical Trial Optional) R34 This initiative supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB), and non-suicidal self-injury (NSSI) specifically among children and adolescents from underserved populations. Applications should focus on developmental work that would enhance the probability of success in subsequent larger scale R01 projects. Research generating new information about factors causing/reducing disparities is strongly encouraged, along with due consideration for the variation in developmental needs across children and youth. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This Funding Opportunity Announcement (FOA) invites development of service strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the future implementation of interventions that are proven effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social and contextual factors, the service strategy under development should account for individual-, family, community-, provider-, and organizational-level factors necessary to optimize effectiveness, feasibility, and rapid uptake, implementation and sustained delivery, thereby accelerating the benefit to the population. The intervention should improve connections to preventive and treatment interventions with proven effectiveness in reducing suicide and suicidal ideation and behaviors, with the goal of making these more available, accessible, and more effectively delivered to underserved youth, in a sustained and coordinated way. This FOA encourages pilot research focused on the development of systems-level interventions and is not intended to support development or testing of new screening tools, assessment instruments, or pilot studies for the development of individual-level preventive or therapeutic interventions. R01 This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide and suicide ideation and behavior (SIB) and/or non-suicidal self-harm (NSSI) by youth from populations that are often underserved by the mental health system. Specifically, this Funding Opportunity Announcement (FOA) encourages services research aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI among adolescents and children from the targeted populations. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. The service strategies to be tested under this announcement should be designed for delivery in typical service settings using commonly available personnel and resources, to enhance implementation and future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the intervention strategies should account for individual-, family-, community-, provider-, and organizational-level factors to optimize effectiveness, feasibility, acceptability, rapid uptake and sustained delivery. The strategy should also improve connections to preventive and treatment interventions with proven effectiveness in reducing SIB or NSSI, with the goal of making these interventions more available, accessible, and more effectively delivered to youth, in a sustained and coordinated way. This FOA encourages research focused on systems-level interventions and is not intended to support the development or testing of new screening tools, assessment instruments, or individual-level preventive or therapeutic interventions. Due June 29, 2021. Med-RA deadline to receive draft documents: June 16. National Institute for Health Care Management (NIHCM) Foundation Investigator-Initiated Health Services Research Grants NIHCM Foundation supports innovative investigator-initiated research with high potential to inform improvements to the U.S. health care system. Projects must advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy. Letter of inquiry due June 30, 2021. Med-RA deadline to receive draft documents: June 18. L.I.F.E. Foundation Research Grants: Brain and Neurodegenerative Diseases George J. Wile established the Local Initiative for Excellence (L.I.F.E.) Foundation in 2014 with a mission to support research to achieve better health outcomes for patients with brain and neurodegenerative disease. The L.I.F.E. Foundation provides research grants to support innovative research, to sustain productive research teams and to encourage and support investigators in the early part of their career. Proposals should focus on basic research to advance understanding of how the brain functions, and proposals exploring how COVID impacts basic brain function will also be considered. The L.I.F.E. Foundation plans to fund up to two grants of $100,000 each (to be awarded over two years $50,000 per year) for reimbursement of approved research expenditures. Brain cancer research and clinical research will not be considered for funding. Letter of intent due June 30, 2021. Med-RA deadline to receive draft documents: June 18. BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R34 / R01 Clinical Trial Not Allowed) R34 This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects ? TargetedBCP R01 (below). Applications should be adventurous exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. R01 This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles. Due July 7, 2021 and November 10, 2021. Med-RA deadline to receive draft documents for July 7 due date: June 23 (due to July 4 holiday). Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations ? RADx-UP Phase II (U01 Clinical Trial Optional) This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics ? Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021. Due July 7, 2021. Med-RA deadline to receive draft documents: June 23 (due to July 4 holiday). Emergency Award: RADx-UP ? Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional) High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021. Due July 7, 2021. Med-RA deadline to receive draft documents: June 23 (due to July 4 holiday). Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) The goal of this funding opportunity announcement (FOA) for the Common Fund Program ?Illuminating the Druggable Genome? (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG?s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Outcomes such as generated tools and data collection by these projects will enhance the overall goals of the IDG Program by expanding the resources available for the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins. The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base. Due July 15, 2021. Med-RA deadline to receive draft documents: July 1 (due to July 4 holiday). Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed) Related: Notice of Special Interest (NOSI) for Illuminating the Druggable Genome (IDG) Initiative: Request for Administrative Supplements to Existing Grants for incorporating single cell data into the IDG Knowledgebase (NOSI expires June 16, 2021.) The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program ?Illuminating the Druggable Genome? (IDG;https://commonfund.nih.gov/idg/ is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the IDG consortium?s Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community?s ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos(https://pharos.nih.gov/idg/index)that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community. The IDG consortium?s purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC). Due July 15, 2021. Med-RA deadline to receive draft documents: July 1 (due to July 4 holiday). End the HIV Epidemic (R01s) Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S. Due July 30, 2021. Med-RA deadline to receive draft documents: July 19. Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this FOA will support the goals of the DIAGNOSE and TREAT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people with HIV through better healthcare engagement. Due August 4, 2021. Med-RA deadline to receive draft documents: July 22. Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities. Due July 30, 2021. Med-RA deadline to receive draft documents: July 19. Understanding HIV Reservoir Dynamics (P01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues. A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy. Due July 30, 2021. Med-RA deadline to receive draft documents: July 19. Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) encourages multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs. Due July 30, 2021. Med-RA deadline to receive draft documents: July 19. Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61 / R33 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages exploratory and developmental bi-phasic research. Applications are solicited to support the understanding of post-transcriptional regulation of intact and defective HIV RNA and to develop therapeutic strategies to alter RNA post-transcriptional modifications as a potential therapeutic platform for inhibiting HIV replication. Due August 4, 2021. Med-RA deadline to receive draft documents: July 22. Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3 / UH3 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV acquisition: men who have sex with men (MSM), people who inject drugs (PWID), and transgender women and men, focusing especially on the minority and age groups at highest risk of HIV transmissions. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV acquisition, comparing those who become HIV-positive to those who do not, and optionally to develop and test digitally-delivered interventions that promote HIV risk reduction to reduce HIV-incidence. Due August 4, 2021. Med-RA deadline to receive draft documents: July 22. Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA?s current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. Due August 10, 2021; March 8, 2022; August 10, 2022; March 8, 2023; August 10, 2023; and March 8, 2024. Med-RA deadline to receive draft documents for August 10, 2021 due date: July 28. Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed) Research funded by this initiative will examine the effects of radiation exposure on the immune system and explore possible treatments for radiation-induced immune dysfunction. Research gaps exist in understanding the mechanisms of injury and repair with regard to radiation-induced immune system dysfunction, and these gaps must be addressed to better develop medical countermeasures (MCMs) for radiation exposure. Through this initiative, the NIAID Radiation and Nuclear Countermeasures Program (RNCP) will support development of animal models for immune-targeted radiation injuries, studies to better understand radiation impacts on the immune system (including immune system-mediated multi-organ injury), identification of immune-specific pathways targeted by radiation, as well as biomarkers of exposure and mitigators/treatments that target immune-related radiation response pathways. Due August 24, 2021. Med-RA deadline to receive draft documents: August 11. Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer?s Disease and Related Dementias (AD/ADRD) (R61 / R33 and R01 Clinical Trial Optional) R61 / R33 This Funding Opportunity Announcement invites R61/R33 applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer?s disease and Alzheimer?s disease-related dementias (AD/ADRD). Mechanisms of adherence may be studied in new, early- to late-stage (including Stage I-IV) behavior change trials. Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that, if modified, will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. Due September 15, 2021. Med-RA deadline to receive draft documents: September 1 (due to Labor Day holiday). R01 This Funding Opportunity Announcement (FOA) invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer?s disease and Alzheimer?s disease-related dementias (AD/ADRD). Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that ? if modified ? will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study. Due September 15, 2021 and January 26, 2022. Med-RA deadline to receive draft documents for September 15 due date: September 1 (due to Labor Day holiday). Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 / R01 ? Clinical Trial Optional) R21 R01 These Funding Opportunity Announcements solicit applications for research projects that will advance translational research to better understand risk and resilience for suicide in the context of the NIMH Research Domain Criteria (RDoC) framework, specifically the Positive Valence Systems (PVS) domain, and lead to novel interventions. The projects should focus on the identification of novel behavioral or neurobiological intervention targets for the treatment of suicidality. NIMH is particularly interested in the role of PVS deficits in suicidal thoughts and behaviors, identification of unique subtypes by behavior and neural circuitry, and associations between PVS-related subtypes and other RDoC domains in relation to suicidality. Due October 5, 2021. Med-RA deadline to receive draft documents: September 22. Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed) The goal of the Innovative Programs to Enhance Research Training (IPERT) initiative is to enable the scientific community to develop and implement innovative educational activities to equip diverse cohorts of participants with technical, operational or professional skills required for careers in the biomedical research workforce, by effectively integrating the required core elements described below: * Courses for Skills Development: For example, support for short courses designed to develop technical (e.g., appropriate and safe methods, technologies, and quantitative/computational approaches), operational (e.g., independent knowledge acquisition, rigorous experimental design, and interpretation of data) and/or professional (e.g., management, leadership, communication, and teamwork) skills necessary to conduct rigorous and reproducible research, and to transition successfully into careers in the biomedical research workforce. These courses could be in-person or provided electronically. Dissemination of educational materials and outreach activities to benefit individuals from a variety of backgrounds are required components of the program. * Mentoring Activities: For example, activities designed to provide career information, advice, and support to research-oriented undergraduates, graduate students, postdoctoral fellows, or independent faculty in biomedical fields. The activities should provide participants with a perspective on the biomedical research training pathway and tools for overcoming challenges, navigating career transition points, and successfully transitioning into careers in the biomedical research workforce. Due October 14, 2021; October 14, 2022; and October 13, 2023. Med-RA deadline to receive draft documents for October 14, 2021 due date: October 4. Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell interventions using novel cell sources, immune-modulatory strategies, biomaterials and devices for T1D treatment. Due October 20, 2021. Med-RA deadline to receive draft documents: October 7. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Apr 30 12:36:04 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 30 Apr 2021 16:36:04 +0000 Subject: Weekly funding opportunities In-Reply-To: <7E061C70-C143-4AE8-A7D7-3CBC1BD75AB6@fsu.edu> References: <7E061C70-C143-4AE8-A7D7-3CBC1BD75AB6@fsu.edu> Message-ID: County Health Rankings and Roadmaps Research Grants: Building a Culture of Health County by County These Research Grants will support scholarly inquiry from outside the program to identify potential improvements to County Health Rankings and Roadmaps (CHR&R) tools to increase their strategic use and the impact of efforts to improve health and increase health equity. The Call for Proposals includes four specific focus areas, informed by Public Health Critical Race Praxis: * Contemporary patterns of racial relations and spatial inequities using the CHR&R data and tools * Knowledge production that supports understanding of the context of racial inequity and systemic racism for inclusion in CHR&R * Conceptualization and measurement of spatial and racial differences that evolve CHR&R data sources, methods, tools, and narratives * Actions to counter racial, spatial, and power inequities to strengthen the potential for CHR&R to contribute to change Up to $600,000 will be available for research under this CFP, with a combination of: * Targeted studies ? up to $50,000 for a maximum of 12 months. * Complex/comprehensive studies ? up to $100,000 for a maximum of 12 months. Applicants seeking higher funding amounts will need to clearly specify the data collection or analysis steps requiring the higher amount. Brief proposals due June 4, 2021. Med-RA deadline to receive draft documents: April 24. Vilcek Prizes For Creative Promise in Biomedical Science Three unrestricted cash prizes of $50,000 each will be awarded to young foreign-born biomedical scientists who demonstrate outstanding early achievement in basic, applied, and/or translational biomedical science. Applicants must have earned a doctoral degree (MD, PhD, or equivalent) and should hold full-time positions at an academic institution or other organization, including positions of assistant or associate professor, or equivalent independent position. To be eligible, applicants must have been born outside the United States; be no older than age 38 as of December 31, 2021 (born on or after January 1, 1983); a naturalized citizen or permanent resident (green card holder) of the United States; and hold an H1B or O-1 visa and have been living and working in the United States for at least five years, or have been granted Deferred Action for Childhood Arrivals (DACA) relief. Due June 11, 2021. Med-RA deadline to receive draft documents: June 1. Trans-Atlantic Platform Recovery, Renewal and Resilience in a Post-Pandemic World (RRR) Call for Proposals Overview Call for Proposals See also NSF Dear Colleague Letter This RRR call emphasizes the following five main challenges related to COVID-19: (i) reducing inequalities and vulnerabilities; (ii) building a more resilient, inclusive and sustainable society; (iii) fostering democratic governance and political participation; (iv) advancing responsible and inclusive digital innovation; and (v) ensuring effective and accurate communication and media. A focus on these five challenges will leverage the social science and humanities research to understand and address the complex societal effects of COVID-19 pandemic, and inform mitigation efforts, thus contributing to a more equitable, resilient and sustainable future. Key to the approach is the added value of new perspectives and insights generated by transnational and interdisciplinary collaborations. Projects should be of 2-3 years in length; funding depends on the countries of origin of the investigators involved in the project. Required intention to submit form due June 14, 2021. Med-RA deadline to receive draft documents: June 1. Robert Wood Johnson Foundation: Health Equity Scholars for Action The goal of the Health Equity Scholars for Action (HES4A) competition is to support the career development and academic advancement of researchers from historically underrepresented backgrounds who conduct health equity research. Grants will be awarded to address the challenges that underrepresented researchers experience; help them overcome obstacles to earning tenure; and make progress toward acquiring independent research funding. Grants will support three aspects of career development: research, mentorship, and connection with a community of support. Eligibility criteria include: applicant must have completed a doctoral degree within the last five years and must be from a historically underrepresented group. Grants of $250,000 each will be awarded through this program. Funds will cover up to 70 percent of the scholar?s salary for two years (capped at $75,000 per year), with the remainder of the award to be used for research and other related expenses. Up to 15 grants will be awarded. Grants will be for 24 months in duration. Letter of intent due June 16, 2021. Med-RA deadline to receive draft documents: June 3. NICHD Small Research Grant Programs (R03 Clinical Trial Required and Basic Experimental Studies with Humans Required) R03 Clinical Trial Required The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. R03 Basic Experimental Studies with Humans Required This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as ?prospective basic science studies involving human participants.? These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3. Michelson Next Generation Grants: Human Vaccines Project The Michelson Prizes: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The 2021 Michelson Prizes will be looking for research proposals in two areas: * Human Immunology and Vaccine Research: The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development. * Climate Change and Human Immunology: Climate change has a profound effect on human health; pollution and other environmental stressors related to climate change increase susceptibility to disease, especially in vulnerable populations. Harnessing the immune system will be critical to mitigate negative health impacts. The committee is looking for research that expands our understanding of the potential effects of climate change on immune function with a particular interest in research that will directly translate into vaccine and immunotherapy development to mitigate its impact. Due June 18, 2021. Med-RA deadline to receive draft documents: June 7. Damon Runyon Cancer Research Foundation Rachleff Innovation Award The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with ?high-risk/high-reward? ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. The Stage 1 award will be for two years, $200,000 per year ($400,000 total) with the opportunity for up to two additional years of funding (up to four years total for $800,000). No IDC. Stage 1 application due July 1, 2021. Med-RA deadline to receive draft documents: June 21. Hope Foundation for Cancer Research: SWOG Early Exploration and Development (SEED) Fund Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the National Clinical Trials Network (NCTN). These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early-stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Direct application to future SWOG research, larger in scope, is critical and will be a metric of success for this funding program. Another metric of success will be the ability to obtain extramural funding based on studies done during the tenure of the support of this grant. Due July 1, 2021 and December 1, 2021. Med-RA deadline to receive draft documents for July 1, 2021 due date: June 21. Congressionally Directed Medical Research Programs Bone Marrow Failure Research Program Idea Development Award Pre-application: July 9, 2021. Invited full application: October 12, 2021. Investigator Initiated Research Award Pre-application: July 9, 2021. Invited full application: October 12, 2021. Med-RA deadline to receive draft documents for pre-application: June 28. Breast Cancer Research Program Breakthrough Award Levels 1 and 2 Pre-application (required letter of intent): August 31, 2021. Full application: September 14, 2021. Med-RA deadline to receive draft documents for full application: August 31 (due to Labor Day holiday). Breakthrough Award Level 3 Pre-application: June 24, 2021. Invited full application: October 5, 2021. Breakthrough Award Level 4 Pre-application: June 24, 2021. Invited full application: October 5, 2021. Med-RA deadline to receive draft documents for pre-application: June 14. Era of Hope Scholar Award Pre-application (required letter of intent): August 31, 2021. Full application: September 14, 2021. Confidential letters of recommendation: September 17, 2021. Med-RA deadline to receive draft documents for full application: August 31 (due to Labor Day holiday). Kidney Cancer Research Program Concept Award Pre-application (required letter of intent): June 22, 2021. Full application: July 13, 2021. Med-RA deadline to receive draft documents for full application: June 29 (due to July 4 holiday). Idea Development Award Pre-application: June 15, 2021. Invited full application: October 5, 2021. Med-RA deadline to receive draft documents for pre-application: June 2. Postdoctoral and Clinical Fellowship Award Pre-application (required letter of intent): June 22, 2021. Full application: July 13, 2021. Med-RA deadline to receive draft documents for full application: June 29 (due to July 4 holiday). Translational Research Fellowship Award Pre-application: June 15, 2021. Invited full application: October 5, 2021. Med-RA deadline to receive draft documents for pre-application: June 2. Lupus Research Program Idea Award Pre-application (required letter of intent): August 24. Full application: September 22. Impact Award Pre-application (required letter of intent): August 24. Full application: September 22. Transformative Vision Award Pre-application (required letter of intent): August 24. Full application: September 22. Med-RA deadline to receive draft documents for full application: September 9. NSF Dear Colleague Letter: Models for Uncovering Rules and Unexpected Phenomena in Biological Systems (MODULUS) The National Science Foundation (NSF) Division of Mathematical Sciences (DMS), in collaboration with the Division of Molecular and Cellular Biosciences (MCB), seeks to promote interdisciplinary research that enables novel mathematical and computational approaches that capture and explore the full range of mechanisms and biological variability needed to better understand complex and nonlinear behavior across multiple biological systems and scales. The development of replicative or descriptive models for complex biological systems remains a challenging task, yet models that move beyond replication into the realm of prediction and ultimately becoming indispensable tools for discovery-driven biology are severely lacking. A paradigm shift in the current approach to interdisciplinary mathematical biology is needed to promote the realization of modeling platforms that facilitate discovery of novel biological phenomena, rules, and theories. As part of the effort, funding opportunities are available in fiscal years FY2021 and FY2022 to provide support for proposals from interdisciplinary teams comprised of mathematical, computational, and biological scientists to develop MODels for Uncovering Rules and Unexpected Phenomena in Biological Systems (MODULUS). This Dear Colleague Letter (DCL) is to encourage researchers involved in the biosciences and the mathematical sciences to collaborate in a substantive manner in biological investigations using novel mechanistic mathematical models to guide biological exploration and discovery of new rules, phenomena, and theories in living systems. Proposals in response to this DCL should be submitted to either DMS via the Mathematical Biology Program or the MCB solicitation, NSF 21-509, directed to the Systems and Synthetic Biology program (8011). The proposal title should be prefaced with ?MODULUS:?. Neither Division puts limits on proposal budgets and expects budgets to be appropriate for the scope of the project proposed. The MCB solicitation accepts proposals without deadline. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten days before submission to sponsor. DARPA: Biological Technologies The mission of BTO is to foster, demonstrate, and transition breakthrough research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences. BTO?s research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO?s programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the Department of Defense (DoD) and addresses national security priorities. Abstracts (highly recommended) and proposals reviewed on a rolling basis. Final deadline to submit abstracts / proposals: April 20, 2022. DARPA proposals have complex administrative requirements. Please notify Med-RA at least two months ahead of anticipated submission deadline. NIH Director?s Early Independence Awards (DP5 Clinical Trial Optional) The NIH Director?s Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director?s Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. Due September 3, 2021. Med-RA deadline to receive draft documents: August 23. Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support the identification of mechanisms behind heterogeneous responses in the population to influenza infection and/or vaccination through development and application of computational tools. Due September 8, 2021. Med-RA deadline to receive draft documents: August 25 (due to Labor Day holiday). BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) The purpose of this Brain Research through Advancing Innovative Neurotechnologies? (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Due October 8, 2021; October 7, 2022; and October 6, 2023. Med-RA deadline to receive draft documents for October 8, 2021 due date: September 27. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: